Hypercalcemia is a condition defined by an elevated level of calcium in the blood. It is a common and potentially serious medical condition that can lead to various cardiac complications. Although the clinical significance of hypercalcemia has been recognized for many years, the underlying mechanisms of its cardiac effects remain elusive. This article will explore the hidden cardiac effects of hypercalcemia from an electrocardiogram (ECG) perspective.
Hypercalcemia is a condition characterized by an abnormally high level of calcium in the blood. It is most commonly caused by primary hyperparathyroidism, malignancy, or certain medications. The normal range of calcium in the blood is 8.5 to 10.5 mg/dL. Hypercalcemia is defined as a calcium level greater than 10.5 mg/dL.
The symptoms of hypercalcemia vary depending on the severity of the condition. Mild hypercalcemia may cause no symptoms at all, while more severe cases can lead to a wide range of symptoms, including: • Muscle weakness • Fatigue • Nausea • Vomiting • Confusion • Abdominal pain • Constipation • Increased thirst • Increased urination
Hypercalcemia can have a number of adverse effects on the heart, including arrhythmias, congestive heart failure, and myocardial infarction. The underlying mechanisms of these cardiac effects are not fully understood, but are thought to involve a combination of electrolyte abnormalities, calcium overload, and altered calcium metabolism.
The ECG is a valuable tool for diagnosing and monitoring hypercalcemia. ECG findings in hypercalcemia can include a prolonged QT interval, ST segment depression, T wave inversion, and atrial and ventricular arrhythmias. These findings can be subtle and may not be immediately apparent on a routine ECG.
QT interval prolongation is one of the most common ECG findings in hypercalcemia. The QT interval is the time between the start of the QRS complex and the end of the T wave. It is a measure of the time taken for the ventricles to depolarize and repolarize. Prolongation of the QT interval can lead to the development of torsades de pointes, a potentially life-threatening arrhythmia.
ST segment depression is another common ECG finding in hypercalcemia. ST segment depression is a downward deflection of the ST segment, which is the period between the end of the QRS complex and the beginning of the T wave. It is a marker of myocardial ischemia and can be seen in hypercalcemia due to the increased workload on the heart.
T wave inversion is another common ECG finding in hypercalcemia. T wave inversion is a downward deflection of the T wave, which is the period between the end of the QRS complex and the beginning of the T wave. It is a marker of myocardial ischemia and can be seen in hypercalcemia due to the increased workload on the heart.
Atrial and ventricular arrhythmias are common in hypercalcemia. These arrhythmias can be caused by electrolyte abnormalities, calcium overload, and altered calcium metabolism. Atrial arrhythmias such as atrial fibrillation and atrial flutter can be seen, as well as ventricular arrhythmias such as ventricular tachycardia and ventricular fibrillation.
Hypercalcemia is a common and potentially serious medical condition that can lead to a variety of cardiac complications. The underlying mechanisms of these cardiac effects are not fully understood, but are thought to involve a combination of electrolyte abnormalities, calcium overload, and altered calcium metabolism. The ECG is a valuable tool for diagnosing and monitoring hypercalcemia, and can be used to detect subtle changes in the heart such as QT interval prolongation, ST segment depression, and T wave inversion
1.
Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy
2.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.
5.
Mouse study finds tirzepatide slowed obesity-associated breast cancer growth
1.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
2.
Teaching Oncologic Emergencies Through Priority-Based Learning
3.
Understanding Protein C Deficiency: Symptoms, Causes, and Treatment
4.
The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies
5.
Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
4.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation